JPH0414089B2 - - Google Patents
Info
- Publication number
- JPH0414089B2 JPH0414089B2 JP813483A JP813483A JPH0414089B2 JP H0414089 B2 JPH0414089 B2 JP H0414089B2 JP 813483 A JP813483 A JP 813483A JP 813483 A JP813483 A JP 813483A JP H0414089 B2 JPH0414089 B2 JP H0414089B2
- Authority
- JP
- Japan
- Prior art keywords
- group
- formula
- lower alkyl
- crystals
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- MDYOLVRUBBJPFM-UHFFFAOYSA-N Tropolone Natural products OC1=CC=CC=CC1=O MDYOLVRUBBJPFM-UHFFFAOYSA-N 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- -1 tropolone compound Chemical class 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 229940041181 antineoplastic drug Drugs 0.000 claims description 3
- 125000005843 halogen group Chemical group 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 239000013078 crystal Substances 0.000 description 19
- FUWUEFKEXZQKKA-UHFFFAOYSA-N beta-thujaplicin Chemical compound CC(C)C=1C=CC=C(O)C(=O)C=1 FUWUEFKEXZQKKA-UHFFFAOYSA-N 0.000 description 18
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 16
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 10
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 10
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 229930007845 β-thujaplicin Natural products 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- 229910052786 argon Inorganic materials 0.000 description 8
- TUFYVOCKVJOUIR-UHFFFAOYSA-N alpha-Thujaplicin Natural products CC(C)C=1C=CC=CC(=O)C=1O TUFYVOCKVJOUIR-UHFFFAOYSA-N 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 239000011541 reaction mixture Substances 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000010898 silica gel chromatography Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000003208 petroleum Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- DHKHKXVYLBGOIT-UHFFFAOYSA-N 1,1-Diethoxyethane Chemical compound CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 3
- FBPNQPMYGLMRDR-UHFFFAOYSA-N 1-ethoxy-3,4-dihydro-1h-isochromene Chemical compound C1=CC=C2C(OCC)OCCC2=C1 FBPNQPMYGLMRDR-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 125000004172 4-methoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C([H])C([H])=C1* 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 150000004699 copper complex Chemical class 0.000 description 2
- OPQARKPSCNTWTJ-UHFFFAOYSA-L copper(ii) acetate Chemical compound [Cu+2].CC([O-])=O.CC([O-])=O OPQARKPSCNTWTJ-UHFFFAOYSA-L 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- ZRSNZINYAWTAHE-UHFFFAOYSA-N p-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1 ZRSNZINYAWTAHE-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- OELWYQGRQUQQPD-IOMDMTNGSA-N (+)-(3R)-1-(3,4-dihydroxyphenyl)-7-phenyl-(6E)-6-hepten-3-ol Chemical compound C([C@@H](O)CCC=1C=C(O)C(O)=CC=1)C\C=C\C1=CC=CC=C1 OELWYQGRQUQQPD-IOMDMTNGSA-N 0.000 description 1
- WARCDZGSKKKAMZ-UHFFFAOYSA-N 1-(diethoxymethyl)-2-methylbenzene Chemical compound CCOC(OCC)C1=CC=CC=C1C WARCDZGSKKKAMZ-UHFFFAOYSA-N 0.000 description 1
- FTTLMNXOYOVHAG-UHFFFAOYSA-N 1-(diethoxymethyl)-4-methoxybenzene Chemical compound CCOC(OCC)C1=CC=C(OC)C=C1 FTTLMNXOYOVHAG-UHFFFAOYSA-N 0.000 description 1
- BVAOFFFFYDZUNU-UHFFFAOYSA-N 1-chloro-2-(diethoxymethyl)benzene Chemical compound CCOC(OCC)C1=CC=CC=C1Cl BVAOFFFFYDZUNU-UHFFFAOYSA-N 0.000 description 1
- 239000001431 2-methylbenzaldehyde Substances 0.000 description 1
- OURGENADILWNDO-UHFFFAOYSA-N 4-butyl-8-methyl-7-(2-oxocyclohexyl)oxychromen-2-one Chemical compound C1=CC=2C(CCCC)=CC(=O)OC=2C(C)=C1OC1CCCCC1=O OURGENADILWNDO-UHFFFAOYSA-N 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 230000009702 cancer cell proliferation Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- MAQMEXSLUSZDQM-UHFFFAOYSA-N diethoxymethylbenzene Chemical compound CCOC(OCC)C1=CC=CC=C1 MAQMEXSLUSZDQM-UHFFFAOYSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- SRCZQMGIVIYBBJ-UHFFFAOYSA-N ethoxyethane;ethyl acetate Chemical compound CCOCC.CCOC(C)=O SRCZQMGIVIYBBJ-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- FXLOVSHXALFLKQ-UHFFFAOYSA-N para-methylbenzaldehyde Natural products CC1=CC=C(C=O)C=C1 FXLOVSHXALFLKQ-UHFFFAOYSA-N 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 125000003944 tolyl group Chemical group 0.000 description 1
- 150000004788 tropolones Chemical class 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Landscapes
- Pyrane Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Description
本発明は新規トロポロン系化合物又はその銅錯
化合物、もしくはそれを有効成分として含有する
抗腫瘍薬に関する。
即ち、本発明は、一般式:
The present invention relates to a novel tropolone compound, a copper complex thereof, or an antitumor drug containing the same as an active ingredient. That is, the present invention is based on the general formula:
【式】【formula】
【式】 又は【formula】 or
【式】
(式中、R1:H又はC1〜C3の低級アルキル基、
R2はC1〜C3の低級アルキル基、メトキシ基また
はハロゲン基で置換されたフエニル基あるいは未
置換のフエニル基、R3はC1〜C3の低級アルキル
基)
で表わされるトロポロン系化合物又はその銅錯化
合物もしくは、それを有効成分とする抗腫瘍薬に
関する。
本発明の化合物は新規なものであり、次の反応
式で示される方法により製造される。
又は
すなわち、トロポロン系化合物、例えば4−イ
ソプロピルトロポロン(ヒノキチオール)と、ベ
ンツアルデヒドジエチルアセタールとの混合物を
加熱すると、3−(α−エトキシベンジル)−6−
イソプロピルトロポロン()及びα,α−ビス
(6−イソプロピル−2−ヒドロキシ−3−トロ
ポリル)トルエン()が得られる。また、トロ
ポロンと、1−エトキシイソクロマンとを同様に
加熱して反応させると、3−(1−イソクロマニ
ル)トロポロン()が得られる。これらのトロ
ポロン系化合物は常法により銅錯塩に導くことが
できる。
上記の方法で得られた化合物は強い抗腫瘍作用
をもち、医薬品としての用途が期待される。
実施例
以下、本発明ついて実施例により更に詳細に説
明する。
実施例 1
3−(α−エトキシベンジル)−6−イソプロピ
ルトロポロン(I−a)(式中、R1=イソプロ
ピル基、R2=フエニル基、R3=エチル基)の
製造。
ベンチアルデヒドジエチルアセタール5.9gと
4−イソプロピルトロポロン4.5gとの混合物を
アルゴン気流中160−170℃で6時間加熱溶融し
た。次いで、反応混合物をシリカゲルカラムクロ
マトで分離精製し、石油エーテル−酢酸エチルの
混合溶媒溶出部分より粘稠な油状物(bp=140
℃/0.005mmHg)(I−a)1g(12%)を得た。
NMR(CDCl3)σ:1.24(6H、d、J=7Hz)、
1.25(3H、t、J=7Hz)、2.85(1H、m)、3.58
(2H、q、J=7Hz)、6.12(1H、s)、6.93−
7.68(7H、m)、7.95(1H、d、J=10Hz)、9.26
(1H、broad)。MS:m/e:298(M+)。Anal.
Calcd C19H22O3:C、76.48:H、7.423。
Foud:C、76.52:H、7.48。
実施例 2
3−(α−エトキシ−4−メチルベンジル)−6
−イソプロピルトロポロン(I−b)(式中、
R1=イソプロピル基、R2=4−ベチルフエニ
ル基、R3=エチル基)の製造
4−メチルベンツアルデヒドエチルアセタール
(6.4g、33mmol)と、ヒノキチオール(2.8g、
17mmol)との混合物をアルゴン気流中150℃で
6時間:加熱撹拌した。反応混合物をシリカゲル
クロマトグラフイーで分離精製して、粘稠な液体
として化合物(I−b)(bp=160−170℃/0.005
mmHg)を1.3g(25%)を得た。
NMR(CDCl3)σ:1.20(3H、t、J=7Hz)、
1.38(6H、d、J=7Hz)、2.29(3H、s)、2.60
−3.20(1H、m)、3.51(1H、q、J=7Hz)、
5.97(1H、s)、6.70−8.00(7H、broad)、8.70−
9.30(1H、broad)。MS:m/e:312(M+)。
Anal.Calcd C20H24O3:C、76.89:H、
7.74Found:C、76.87:H7.80。
実施例 3
3−(α−エトキシ−4−メトキシベンジル)−
6−イソプロピルトロポロン(I−c)(式中、
R1=イソプロピル基、R2=4−メトキシフエ
ニル基、R3=エチル基)の製造
4−メトキシベンツアルデヒドジエチルアセタ
ール(5.5g、26mmol)と、ヒノキチオール
(4g、24mmol)との混合物をアルゴン気流中
150℃で10時間加熱した。反応混合物をシリカゲ
ルカラムクロマトグラフイーで分離精製して、
1.5g(18.5%)の粘稠な液体(I−c)を得た。
(bp=180℃/0.005mmHg)。
NMR(CDCl3)σ:1.30(6H、d、J=7Hz)、
1.30(3H、t、J=7Hz)、2.85(1H、m)、3.58
(2H、q、J=7Hz)、3.80(3H、s)、6.08(1H、
s)、6.70−7.60(7H、m)、8.05(1H、d、J=
10Hz)。MS:m/e:328(M+)。Anal.Calcd
C20H24O4:C、73.14:H、7.37Foud:C、
73.32H、7.50。
実施例 4
α,α−ビス(6−イソプロピル−2−ヒドロ
キシ−3−トロポリル)トルエン(−a)
(式中、R1=イソプロピル基、R2=フエニル
基)の製造
実施例1の方法でシリカゲルカラムクロマトに
よるI−aの溶出についで第2の溶出部から
mp.199−200℃の結晶(−a)3.16g(28%)
を得た。
NMR(CDCl3)σ:1.27(12H、d、J=7
Hz)、2.48−3.26(2H、s)、6.76(1H、s)、6.82
−7.44(10H、m)、9.53(2H、broad)。MS:
m/e:416(M+)。Anal.Calcd C27H28O4:C、
77.86:H、6.78Foud:C、77.79:H、6.82。
実施例 5
α,α−ビス(6−イソプロピル−2−ヒドロ
キシ−3−トロポリル)−4−メトキシトルエ
ン(−a)(式中、R1=イソプロピル基、R2
=4−メトキシフエニル基)の製造
ヒノキチオール(4g、24mmol)と、アニス
アルデヒドジエチルアセタール(2.5g、12m
mol)との混合物をアルゴン気流中180℃で2時
間加熱した。反応後、熱メタノールに溶し、冷却
して結晶を析出させた。結晶をろ取し、母液を濃
縮して、シリカゲルを用いてカラムクロマトグラ
フイーで分離し、結晶を析出させた。前にろ取し
た結晶と合せてエタノールより再結晶して、
mp.204〜205℃の結晶(−b)を得た〔収量1.8
g(33.6%)〕。
NMR(CDCl3)σ:1.30(12H、d、J=7
Hz)、2.48−3.24(2H、m)、3.85(3H、s)6.56
(1H、s)、6.60−7.51(10H、m)、9.02(2H、
broad)。MS:m/e:446(M+)。Anal.Calcd
C27H30O5:C、75.31:H、6.77Foud:C、
75.42:H、6.75。
実施例 6
α,α−ビス(6−イソプロピル−2−ヒドロ
キシ−3−トロポリル)−4−メチルトルエン
(−c)(式中、R1=イソプロピル基、R2=
メチルフエニール基)の製造
ヒノキチオール(3.28g、20mmol)と、4−
メチルベンツアルデヒドジエチルアセタール
(2.4g、12mmol)との混合物をアルゴン気流
中、180℃で6時間加熱した。反応液に石油エー
テルを加えて析出する結晶をろ取し、母液はシリ
カゲルを用いてカラムクロマトグラフイーで分離
した。石油エーテルと酢酸エチルとの混合溶液で
溶出する部分から結晶を得た。前にろ取した結晶
と合せ、ベンゼンより再結晶して、mp.231〜233
℃の結晶(−c)1.60g(37.2%)を得た。
NMR(CDCl3)σ:1.28(12H、d、J=6
Hz)、2.37(3H、s)、2.50−3.30(2H、m)、6.65
(1H、s)、6.70−7.50(10H、broad)、9.00−9.72
(2H、broad)。MS:m/e:430(M+)。Anal.
Calcd C28H30O4:C、78.10:H、7.04。
Found:C、78.19:H、7.11。
実施例 7
α,α−ビス(6−イソプロピル−2−ヒドロ
キシ−3−トロポリル)−4−クロロトルエン
(−c)(式中、R1=イソプロピル基、R2=
4−フロロフエニル基)の製造
ヒノキチオール(3.28g、20mmol)と、4−
クロロベンツアルデヒドジエチルアセタール
(2.57g、12mmol)との混合物をアルゴン気流
中、180℃で6時間加熱した。反応混合物に石油
エーテルを加えて析出する結晶をろ取し、母液は
シリカゲルを用いてカラムクロマトグラフイーで
分離した。石油エーテル−酢酸エチル(32:1)
の混合溶媒で溶出し、結晶を析出せさた。前にろ
取した結晶と合せてベンゼンから再結晶して、
mp.227〜228℃の結晶(−d)を得た〔収量1.6
g(35%)〕
NMR(CDCl3)σ:1.14(12H、d、J=8
Hz)、2.35−3.15(2H、m)、6.62(1H、s)、6.67
−7.55(10H、broad)、9.05−9.70(2H、broad)。
MS:m/e:451(M+)。Anal.Calcd
C27H27O4Cl:C、71.90:H、6.05。Found:C、
71.66:H、5.98。
実施例 8
α,α−ビス(6−イソプロピル−2−ヒドロ
キシ−3−トロポリル)−4−メトキシトルエ
ン−銅錯塩(Ib−Cu)(式中、R1=イソプロピ
ル基、R2=4−メトキシフエニル基)の製造
実施例5の方法で得た−b(0.5g、1.12m
mol)を30mlのクロロホルムに溶かし、これに酢
酸銅(0.5g、2.2mmol)を少量の水に懸濁させ
たものを加えて2時間撹拌した。クロロホルム層
を分取し、水洗、乾燥後溶媒を濃縮して、
mp.300℃以上の緑色結晶を0.49g(85%)を得
た。Anal.Calcd C29H28O5:Cu:C、70.29:H、
5.83。Found:C、70.41:H、5.91。
実施例 9
3−(1−イソクロマニル)−6−イソプロピル
トロポロン(−a)(式中、R1=イソプロピ
ル基)の製造
1−エトキシイソクロマン8.15g(45mmol)
と、ヒノキチオール5g(30mmol)とをアルゴ
ン気流中で150−160℃に8時間加熱溶融した。反
応混合物をシリカゲルカラムクロマトで分離精製
して、ベンゼン溶出部から、mp.135−138℃の結
晶(−a)4.13g(46%)を得た。
NMR(CDCl3)σ:1.23(6H、d、J=7Hz)、
2.50−3.50(3H、m)、3.80−4.45(2H、m)、6.62
(1H、s)、6.72−7.40(7H、m)、7.50(1H、d、
J=10Hz)、9.30(1H、broad)。MS:m/e:
296(M+)。Anal.Calcd C19H20O3:C、77.00:
H、6.80。Found:C、77.23:H、6.92。
実施例 10
3−(1−イソクロマニル)トロポロン(−
b)(式中、R1=H)の製造
1−エトキシイソクロマン2.9g(16mmol)
と、トロポロン1.3g(10mmol)の混合物をア
ルゴン気流中で150−160℃に15時間加熱溶融し
た。反応混合物をシリカゲルカラムクロマトで分
離精製して、石油エーテル−酢酸エチルの混合溶
媒溶出部からmp.175−178℃の結晶(−b)
1.25g(46%)を得た。
NMR(CDCl3)σ:2.53−3.51(2H、m)、3.80
−4.54(2H、m)、6.65(1H、s)、6.73−7.71
(7H、m)、9.03−9.65(1H、broad)。MS:m/
e:245(M+)。Anal.Calcd C16H14O3:C、
75.57:H、5.55。Found:C、75.61:H、5.51
実施例 11
3−(1−イソクロマニル)−6−イソプロピル
トロポロン−銅錯塩(−a−Cu)(式中、R1
=イソプロピル基)の製造
実施例9で得た化合物−a1gと、酢酸銅0.8
gとを、メタノール50mlとクロロホルム50mlに溶
かし、室温で2時間撹拌した。反応混合物をクロ
ロホルムで抽出し、クロロホルム層を分取し、水
洗し、乾燥した後、溶媒を濃縮して、mp.290°以
上の緑色結晶(−a−Cu)1g(83%)を得
た。
抗腫瘍試験
KB−細胞増殖抑制試験
この試験は、KBB細胞をEagl′es minimal
essentiai medium(MEM)−10%Calf serm培地
に入れ、5%炭酸ガス培養器中37℃で培養したも
のを用いて実施した。まず、初日にKB細胞を2
×104/ml個を含むように希釈し、その3mlを60
mmの時計皿に植えた。次いで、第2日目に試験物
をそれぞれ100、30、10、3及び1μg/mlとなる
ように加えて同様に培養した。最後に、第4日目
に生存した細胞を時計皿面よりトリプシンを用い
てはずし、細胞数を計測した。このとき、細胞数
が薬物を加えなかつた方のコントロールに比して
実質50%の増殖抑制を示すのに必要とした薬物の
濃度(ED50)を求め、その薬物と癌細胞増殖抑
制効果として表現した。その結果を表1に示す。
担がんマウスの延命効果試験
CDFマウスの6匹を1グループとしてP388腫
瘍の細胞106個を各マウスに移植した後、第1日
及び第5日目に試験薬物をマウスの腹腔内に投与
した。延命の効果の判定は無処理群の生存日数に
対する投与群の生存日数の比(T/C%)で表示
した。その結果を上記表1に示す。[Formula] (wherein, R 1 is H or a C 1 to C 3 lower alkyl group,
Tropolone compound represented by R 2 is a C 1 to C 3 lower alkyl group, a phenyl group substituted with a methoxy group or a halogen group, or an unsubstituted phenyl group, and R 3 is a C 1 to C 3 lower alkyl group or a copper complex thereof, or an antitumor drug containing the same as an active ingredient. The compound of the present invention is novel and can be produced by the method shown in the following reaction formula. or That is, when a mixture of a tropolone compound such as 4-isopropyltropolone (hinokitiol) and benzaldehyde diethyl acetal is heated, 3-(α-ethoxybenzyl)-6-
Isopropyltropolone ( ) and α,α-bis(6-isopropyl-2-hydroxy-3-tropolyl)toluene ( ) are obtained. Furthermore, when tropolone and 1-ethoxyisochroman are heated and reacted in the same manner, 3-(1-isochromanyl)tropolone () is obtained. These tropolone compounds can be converted into copper complex salts by conventional methods. The compounds obtained by the above method have strong antitumor effects and are expected to be used as pharmaceuticals. EXAMPLES Hereinafter, the present invention will be explained in more detail with reference to Examples. Example 1 Preparation of 3-(α-ethoxybenzyl)-6-isopropyltropolone (I-a) (wherein R1 = isopropyl group, R2 = phenyl group, R3 = ethyl group). A mixture of 5.9 g of benchaldehyde diethyl acetal and 4.5 g of 4-isopropyltropolone was heated and melted at 160-170 DEG C. for 6 hours in an argon stream. Next, the reaction mixture was separated and purified using silica gel column chromatography, and a viscous oil (bp=140
℃/0.005 mmHg) (Ia) 1 g (12%) was obtained. NMR (CDCl 3 ) σ: 1.24 (6H, d, J = 7Hz),
1.25 (3H, t, J=7Hz), 2.85 (1H, m), 3.58
(2H, q, J=7Hz), 6.12 (1H, s), 6.93−
7.68 (7H, m), 7.95 (1H, d, J=10Hz), 9.26
(1H, broad). MS: m/e: 298 (M + ). Anal.
Calcd C19H22O3 : C, 76.48 :H, 7.423.
Foud: C, 76.52: H, 7.48. Example 2 3-(α-ethoxy-4-methylbenzyl)-6
-isopropyltropolone (Ib) (wherein,
Production of R 1 = isopropyl group, R 2 = 4-betyl phenyl group, R 3 = ethyl group) 4-methylbenzaldehyde ethyl acetal (6.4 g, 33 mmol) and hinokitiol (2.8 g,
(17 mmol) was heated and stirred at 150° C. for 6 hours in an argon stream. The reaction mixture was separated and purified by silica gel chromatography to obtain compound (I-b) (bp=160-170℃/0.005) as a viscous liquid.
mmHg) was obtained (1.3 g (25%)). NMR (CDCl 3 ) σ: 1.20 (3H, t, J = 7Hz),
1.38 (6H, d, J=7Hz), 2.29 (3H, s), 2.60
-3.20 (1H, m), 3.51 (1H, q, J=7Hz),
5.97 (1H, s), 6.70−8.00 (7H, broad), 8.70−
9.30 (1H, broad). MS: m/e: 312 (M + ).
Anal.Calcd C 20 H 24 O 3 :C, 76.89:H,
7.74 Found: C, 76.87: H7.80. Example 3 3-(α-ethoxy-4-methoxybenzyl)-
6-isopropyltropolone (I-c) (wherein,
Production of R 1 = isopropyl group, R 2 = 4-methoxyphenyl group, R 3 = ethyl group) A mixture of 4-methoxybenzaldehyde diethyl acetal (5.5 g, 26 mmol) and hinokitiol (4 g, 24 mmol) was heated with argon. in airflow
Heated at 150°C for 10 hours. The reaction mixture was separated and purified using silica gel column chromatography.
1.5 g (18.5%) of a viscous liquid (Ic) was obtained.
(bp=180℃/0.005mmHg). NMR (CDCl 3 ) σ: 1.30 (6H, d, J = 7Hz),
1.30 (3H, t, J=7Hz), 2.85 (1H, m), 3.58
(2H, q, J=7Hz), 3.80 (3H, s), 6.08 (1H,
s), 6.70−7.60 (7H, m), 8.05 (1H, d, J=
10Hz). MS: m/e: 328 (M + ). Anal.Calcd
C20H24O4 : C, 73.14 :H, 7.37Foud:C,
73.32H, 7.50. Example 4 α,α-bis(6-isopropyl-2-hydroxy-3-tropolyl)toluene (-a)
(In the formula, R 1 = isopropyl group, R 2 = phenyl group) Following the elution of I-a by silica gel column chromatography according to the method of Example 1, from the second elution part
mp.199-200℃ crystal (-a) 3.16g (28%)
I got it. NMR (CDCl 3 )σ: 1.27 (12H, d, J=7
Hz), 2.48−3.26 (2H, s), 6.76 (1H, s), 6.82
−7.44 (10H, m), 9.53 (2H, broad). MS:
m/e: 416 (M + ). Anal.Calcd C 27 H 28 O 4 :C,
77.86:H, 6.78Foud:C, 77.79:H, 6.82. Example 5 α,α-bis(6-isopropyl-2-hydroxy-3-tropolyl)-4-methoxytoluene (-a) (wherein R 1 =isopropyl group, R 2
= 4-methoxyphenyl group) Production of hinokitiol (4 g, 24 mmol) and anisaldehyde diethyl acetal (2.5 g, 12 mmol)
mol) was heated at 180° C. for 2 hours under a stream of argon. After the reaction, it was dissolved in hot methanol and cooled to precipitate crystals. The crystals were collected by filtration, the mother liquor was concentrated, and the crystals were separated by column chromatography using silica gel to precipitate crystals. Recrystallize from ethanol together with the crystals collected by filtration before.
Crystals (-b) with mp.204-205℃ were obtained [yield 1.8
g (33.6%)]. NMR (CDCl 3 )σ: 1.30 (12H, d, J=7
Hz), 2.48−3.24 (2H, m), 3.85 (3H, s) 6.56
(1H, s), 6.60−7.51 (10H, m), 9.02 (2H,
broad). MS: m/e: 446 (M + ). Anal.Calcd
C27H30O5 : C, 75.31 :H, 6.77Foud:C,
75.42:H, 6.75. Example 6 α,α-bis(6-isopropyl-2-hydroxy-3-tropolyl)-4-methyltoluene (-c) (wherein R 1 = isopropyl group, R 2 =
Production of methylphenyl group) Hinokitiol (3.28g, 20mmol) and 4-
A mixture of methylbenzaldehyde diethyl acetal (2.4 g, 12 mmol) was heated at 180° C. for 6 hours under a stream of argon. Petroleum ether was added to the reaction solution, and the precipitated crystals were collected by filtration, and the mother liquor was separated by column chromatography using silica gel. Crystals were obtained from the portion eluted with a mixed solution of petroleum ether and ethyl acetate. Combined with the crystals collected earlier and recrystallized from benzene, mp.231-233
1.60 g (37.2%) of crystals (-c) were obtained. NMR (CDCl 3 ) σ: 1.28 (12H, d, J=6
Hz), 2.37 (3H, s), 2.50−3.30 (2H, m), 6.65
(1H, s), 6.70−7.50 (10H, broad), 9.00−9.72
(2H, broad). MS: m/e: 430 (M + ). Anal.
Calcd C28H30O4 : C, 78.10 :H, 7.04.
Found: C, 78.19: H, 7.11. Example 7 α,α-bis(6-isopropyl-2-hydroxy-3-tropolyl)-4-chlorotoluene (-c) (wherein R 1 = isopropyl group, R 2 =
Production of hinokitiol (3.28 g, 20 mmol) and 4-fluorophenyl group)
A mixture of chlorobenzaldehyde diethyl acetal (2.57 g, 12 mmol) was heated at 180° C. for 6 hours under a stream of argon. Petroleum ether was added to the reaction mixture, and the precipitated crystals were collected by filtration, and the mother liquor was separated by column chromatography using silica gel. Petroleum ether-ethyl acetate (32:1)
It was eluted with a mixed solvent of , and crystals were precipitated. Recrystallize from benzene together with the crystals filtered earlier,
Crystals (-d) with mp.227-228℃ were obtained [yield 1.6
g (35%)] NMR (CDCl 3 ) σ: 1.14 (12H, d, J = 8
Hz), 2.35−3.15 (2H, m), 6.62 (1H, s), 6.67
−7.55 (10H, broad), 9.05−9.70 (2H, broad).
MS: m/e: 451 (M + ). Anal.Calcd
C27H27O4Cl : C, 71.90 :H, 6.05. Found:C,
71.66:H, 5.98. Example 8 α,α-bis(6-isopropyl-2-hydroxy-3-tropolyl)-4-methoxytoluene-copper complex salt (Ib-Cu) (wherein R 1 = isopropyl group, R 2 = 4-methoxy -b (0.5g, 1.12m) obtained by the method of Example 5
mol) in 30 ml of chloroform, a suspension of copper acetate (0.5 g, 2.2 mmol) in a small amount of water was added thereto, and the mixture was stirred for 2 hours. Separate the chloroform layer, wash with water, dry, and concentrate the solvent.
0.49g (85%) of green crystals with mp.300°C or higher were obtained. Anal.Calcd C 29 H 28 O 5 :Cu:C, 70.29:H,
5.83. Found: C, 70.41: H, 5.91. Example 9 Production of 3-(1-isochromanyl)-6-isopropyltropolone (-a) (in the formula, R 1 = isopropyl group) 1-ethoxyisochroman 8.15 g (45 mmol)
and 5 g (30 mmol) of hinokitiol were heated and melted at 150-160° C. for 8 hours in an argon stream. The reaction mixture was separated and purified using silica gel column chromatography, and 4.13 g (46%) of crystals (-a) with a mp. of 135-138°C was obtained from the benzene eluate. NMR (CDCl 3 ) σ: 1.23 (6H, d, J = 7Hz),
2.50−3.50 (3H, m), 3.80−4.45 (2H, m), 6.62
(1H, s), 6.72−7.40 (7H, m), 7.50 (1H, d,
J=10Hz), 9.30 (1H, broad). MS: m/e:
296 (M + ). Anal.Calcd C 19 H 20 O 3 :C, 77.00:
H, 6.80. Found: C, 77.23: H, 6.92. Example 10 3-(1-isochromanyl)tropolone(-
b) Production of (in the formula, R 1 =H) 1-ethoxyisochromane 2.9 g (16 mmol)
and 1.3 g (10 mmol) of tropolone were heated and melted at 150-160° C. for 15 hours in an argon stream. The reaction mixture was separated and purified using silica gel column chromatography, and crystals at mp.175-178°C were obtained from the eluate of a mixed solvent of petroleum ether and ethyl acetate (-b)
1.25g (46%) was obtained. NMR ( CDCl3 ) σ: 2.53−3.51 (2H, m), 3.80
−4.54 (2H, m), 6.65 (1H, s), 6.73−7.71
(7H, m), 9.03−9.65 (1H, broad). MS: m/
e: 245 (M + ). Anal.Calcd C 16 H 14 O 3 :C,
75.57:H, 5.55. Found: C, 75.61: H, 5.51 Example 11 3-(1-isochromanyl)-6-isopropyltropolone-copper complex salt (-a-Cu) (in the formula, R 1
= isopropyl group) 1g of the compound-a obtained in Example 9 and 0.8g of copper acetate
g was dissolved in 50 ml of methanol and 50 ml of chloroform, and the mixture was stirred at room temperature for 2 hours. The reaction mixture was extracted with chloroform, the chloroform layer was separated, washed with water, dried, and the solvent was concentrated to obtain 1 g (83%) of green crystals (-a-Cu) with mp.290° or higher. . Antitumor Test KB-Cell Proliferation Inhibition Test This test uses KBB cells as minimal
The experiment was carried out using medium (MEM)-10% Calf Serm medium and cultured at 37°C in a 5% carbon dioxide incubator. First, on the first day, 2 KB cells were
Dilute to contain ×10 4 /ml, and add 3 ml to 60
Planted in mm watch glass. Then, on the second day, test substances were added at 100, 30, 10, 3, and 1 μg/ml, respectively, and cultured in the same manner. Finally, cells that survived on the fourth day were removed from the watch glass using trypsin, and the number of cells was counted. At this time, the concentration of the drug required to actually inhibit cell proliferation by 50% compared to the control without the addition of the drug (ED 50 ) was determined, and the drug and cancer cell proliferation inhibitory effect were determined. expressed. The results are shown in Table 1. Life extension effect test on tumor-bearing mice After transplanting 106 P388 tumor cells into each group of 6 CDF mice, the test drug was administered intraperitoneally to the mice on the 1st and 5th day. did. The survival effect was evaluated as the ratio (T/C%) of the survival days of the treated group to the survival days of the untreated group. The results are shown in Table 1 above.
【表】【table】
Claims (1)
換されたフエニル基あるいは未置換のフエニル
基、R3はC1〜C3の低級アルキル基を示す、)、 (たヾし、R1、R2は既に定義した通りである。)
又は、 【式】を示す〕 で表されるトロポロン系化合物又はその銅錯化合
物。 2 一般式: 〔式中、 R1はH又はC1〜C3の低級アルキル基を示し; Qは【式】(たヾし、R2はC1〜C3の低 級アルキル基、メトキシ基またはハロゲン基で置
換されたフエニル基あるいは未置換のフエニル
基、R3はC1〜C3の低級アルキル基を示す、)、 (たヾし、R1、R2は既に定義した通りである。)
又は、 【式】を示す〕 を有効成分とする抗腫瘍薬。[Claims] 1. General formula: [Wherein, R 1 represents H or a C 1 to C 3 lower alkyl group; Q is [Formula] (wherein, R 2 is a C 1 to C 3 lower alkyl group, a methoxy group, or a halogen group Substituted phenyl group or unsubstituted phenyl group, R 3 represents a C 1 to C 3 lower alkyl group), (However, R 1 and R 2 are as defined already.)
Or, a tropolone compound or its copper complex compound represented by [Formula]]. 2 General formula: [Wherein, R 1 represents H or a C 1 to C 3 lower alkyl group; Q is [Formula] (wherein, R 2 is a C 1 to C 3 lower alkyl group, a methoxy group, or a halogen group Substituted phenyl group or unsubstituted phenyl group, R 3 represents a C 1 to C 3 lower alkyl group), (However, R 1 and R 2 are as defined already.)
Or, an antitumor drug containing [Formula]] as an active ingredient.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP813483A JPS59134720A (en) | 1983-01-20 | 1983-01-20 | Antitumor agent |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP813483A JPS59134720A (en) | 1983-01-20 | 1983-01-20 | Antitumor agent |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP18108783A Division JPS59134744A (en) | 1983-09-28 | 1983-09-28 | Tropolone derivative having antitumor action |
| JP58181088A Division JPS59134745A (en) | 1983-09-28 | 1983-09-28 | Tropolone derivative having antitumor action |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS59134720A JPS59134720A (en) | 1984-08-02 |
| JPH0414089B2 true JPH0414089B2 (en) | 1992-03-11 |
Family
ID=11684813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP813483A Granted JPS59134720A (en) | 1983-01-20 | 1983-01-20 | Antitumor agent |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS59134720A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2864311A4 (en) * | 2012-06-22 | 2015-12-02 | Univ Connecticut | SUBSTITUTED TROPOLONE DERIVATIVES AND METHODS OF USE |
-
1983
- 1983-01-20 JP JP813483A patent/JPS59134720A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS59134720A (en) | 1984-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS63275582A (en) | Production of 1-aminoimidazo(4,5-b)pyridine derivative | |
| JPS59134745A (en) | Tropolone derivative having antitumor action | |
| RU2198875C2 (en) | Methods of synthesis of pyridine-2-carboxaldehyde thiosemicarbazones and intermediate pyridine-2-carboxaldehydes | |
| JPH03109384A (en) | Production of (s)-4-hydroxymethyl-gamma-lactone | |
| Shimizu et al. | Synthesis and absolute configuration of optically active selenoxides. X-Ray molecular structure of (–) se-4-menthyloxycarbonylphenyl 2, 4, 6-tri-isopropylphenyl selenoxide | |
| US5200536A (en) | Fluorine-containing vitamin D3 analogues | |
| JPS61129145A (en) | Manufacture of hydroquinone derivative | |
| JPH0414089B2 (en) | ||
| Kelly et al. | 2, 2, 2-Triphenyl-4, 5-(2', 2"-biphenylene)-1, 3, 2-dioxaphospholane: an effective reagent for converting diols, amino alcohols, and especially mercapto alcohols to the corresponding heterocycles | |
| EP0062068B1 (en) | N-phthalidyl-5-fluorouracil derivatives | |
| CN111253334A (en) | Mild photocatalytic synthesis method of C2 ether substituted 2H-benzothiazole derivative | |
| JP2832479B2 (en) | Stereochemical inversion method of optically active styrene oxide and preparation of optically active glycol derivative | |
| SU1530094A3 (en) | Method of obtaining condensed derivatives of ac-triazine | |
| JP3432880B2 (en) | Preparation of optically active azaspiro compounds | |
| JPH085880B2 (en) | Antibiotic diazaquinomycin A derivative | |
| JPS61215341A (en) | Production of tropolone derivative and use as antitumor agent | |
| JPS59134744A (en) | Tropolone derivative having antitumor action | |
| JP2527555B2 (en) | Phosphine oxide perhalogenate | |
| JP2543703B2 (en) | Method for producing organic germanium compound | |
| JPH0662470B2 (en) | Process for producing optically active hexa-2,4-diyne-1,6-diols | |
| JPH03275636A (en) | Cyclopentene derivative and intermediate for producing the same | |
| SU470111A3 (en) | The method of obtaining 5- (3 "-phenyl-1" -oxypropyl) -6-dialkylaminoalkoxy-4,7-dimethoxybenzofuran derivatives | |
| JPH0692401B2 (en) | 1,4-dihydropyridine derivative | |
| JPS6111231B2 (en) | ||
| JPH0733769A (en) | Pyrazolopyridine derivative and method for producing the same |